Daniel Sem
Angel Investor @ Talents Fund
Milwaukee, United States
Daniel Sem is a seed investor at Talents Fund in Milwaukee focused on Pharmaceutical and Medical. Dr. Sem is also Dean and Professor of Business, Professor of Pharmaceutical Sciences, and Director of Technology Transfer at Concordia University Wisconsin. He also serves on the editorial board of PLoS One Life Sciences, the Board of Directors for the BBB, and for Ozaukee County Economic Development Corp. Dr. Sem has over 20 years of experience indrug discovery and development and has over 60 papers and 10 issued patents. He co-founded two drug discovery and development companies (Triad and AviMed) and one social venture (Bridge to Cures) before Retham. He served as VP for Biophysics at Triad Therapeutics, where he developed a platform technology for designing focused combinatorial libraries targeting kinases and dehydrogenases. He co-founded Triad Therapeutics based on technology he developed and patented, and he assisted in securing two rounds of venture financing, totaling over $40 million. Triad was voted one of the top 10 biotech startups in the U.S. in 2001 by Drug Discovery Today, and licensed kinase drug leads to Novartis for up to $60 million. Dr. Sem received his B.S. in Chemistry from UW-Milwaukee, his Ph.D. from UW-Madison in Biochemistry, and his MBA and JD degrees from Marquette University.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Daniel Sem invests in
Stages Daniel Sem invests in
Countries Daniel Sem invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Pharmaceutical 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Retham Technologies is a biotech business that enables HIT testing to diagnose heparin-induced thrombocytopenia. They develop an IVD assay for patient HIT diagnosis is expected to facilitate timely and appropriate therapy. | $1.5M / Seed / Sep 15, 2026 | ||
| Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company focused on developing the next generation of innovative therapies to improve menopausal women's mental health. Estrigenix Therapeutics was formed in 2018 to improve women’s health, focusing initially on the physical and mental effects of menopause. | $2M / Seed / Jul 21, 2026 |
Co-Investors
About Talents Fund
Talents Fund is a seed-stage venture capital firm focused on investing in breakthrough life sciences and biotechnology startups.
Talents Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Curt Gielow
Co-Founder & Partner
|
|||
Daniel Becker
Co-Founder , Partner & CFO
|
|||
Daniel Sem
Founder & Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Daniel Sem invest in?
Daniel Sem invests primarily in Pharmaceutical, Medical and Health Care startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daniel Sem?
Public channels for Daniel Sem include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Daniel Sem last invest?
The most recent investment recorded for Daniel Sem closed in Sep 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
